We show, for the first time, that inhibition of LDH-A can notably enhance the inhibitory effects of PARP inhibitors on ovarian cancer with wild-type BRCA, which could be considered as a novel treatment. This evidence concerns the gene PARP1 and ovarian carcinoma.